MA49830A - Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl - Google Patents
Traitement à l'obinutuzumab d'un sous-groupe de patients dlbclInfo
- Publication number
- MA49830A MA49830A MA049830A MA49830A MA49830A MA 49830 A MA49830 A MA 49830A MA 049830 A MA049830 A MA 049830A MA 49830 A MA49830 A MA 49830A MA 49830 A MA49830 A MA 49830A
- Authority
- MA
- Morocco
- Prior art keywords
- patient subgroup
- dlbcl patient
- obinutuzumab
- treatment
- obinutuzumab treatment
- Prior art date
Links
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title 1
- 229960003347 obinutuzumab Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542489P | 2017-08-08 | 2017-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49830A true MA49830A (fr) | 2021-03-31 |
Family
ID=63209389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049830A MA49830A (fr) | 2017-08-08 | 2018-08-08 | Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11597772B2 (fr) |
| EP (1) | EP3665196B1 (fr) |
| JP (2) | JP7418322B2 (fr) |
| KR (1) | KR102799421B1 (fr) |
| CN (2) | CN111032692A (fr) |
| AU (1) | AU2018314765C1 (fr) |
| CA (1) | CA3071618A1 (fr) |
| CR (1) | CR20200061A (fr) |
| ES (1) | ES2933256T3 (fr) |
| IL (1) | IL272418B2 (fr) |
| MA (1) | MA49830A (fr) |
| MX (1) | MX2020001493A (fr) |
| MY (1) | MY202382A (fr) |
| PE (1) | PE20200738A1 (fr) |
| PL (1) | PL3665196T3 (fr) |
| SG (1) | SG11202000985XA (fr) |
| TW (1) | TWI772488B (fr) |
| UA (1) | UA126204C2 (fr) |
| WO (1) | WO2019030260A1 (fr) |
| ZA (1) | ZA202000680B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023247A1 (fr) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand |
| CA3071618A1 (fr) * | 2017-08-08 | 2019-02-14 | F. Hoffmann-La Roche Ag | Traitement a l'obinutuzumab d'un sous-groupe de patients dlbcl |
| CA3118312A1 (fr) * | 2018-10-29 | 2020-05-07 | Tigatx, Inc. | Compositions et methodes comprenant des constructions d'anticorps iga |
| EP3918323A4 (fr) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | Anticorps anti-gal3 et leurs utilisations |
| WO2021242776A2 (fr) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870562A (en) | 1986-03-20 | 1989-09-26 | Nec Corporation | Microcomputer capable of accessing internal memory at a desired variable access time |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| EP0999853B1 (fr) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Formulation stabilisee renfermant un anticorps |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| GB0718684D0 (en) * | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
| US20130195843A1 (en) * | 2010-06-23 | 2013-08-01 | British Columbia Cancer Agency Branch | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof |
| ES2738289T3 (es) * | 2013-11-06 | 2020-01-21 | Hospital Clinic Barcelona | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| DE102013222576A1 (de) | 2013-11-06 | 2015-05-07 | BSH Bosch und Siemens Hausgeräte GmbH | Haushaltsgerät |
| PL3066126T3 (pl) | 2013-11-07 | 2019-08-30 | F. Hoffmann-La Roche Ag | Leczenie skojarzone z zastosowaniem niefukozylowanego przeciwciała anty-CD20 i inhibitora BTK |
| CN107002119A (zh) * | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
| EP3193932B1 (fr) * | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Formulations d'anticorps |
| EP3689910A3 (fr) * | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Procédé d'utilisation d'immunoconjugués anti-cd79b |
| EA201792300A1 (ru) * | 2015-06-08 | 2018-09-28 | Дебиофарм Интернэшнл, С.А. | Комбинации иммуноконъюгата к cd37 и антитела к cd20 |
| KR20180012873A (ko) | 2015-06-24 | 2018-02-06 | 에프. 호프만-라 로슈 아게 | 림프종 또는 백혈병에서 림프구증가증의 유도에 사용하기 위한 인간 csf-1r에 대한 항체 |
| EP3178848A1 (fr) * | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Anticorps de type ii contre cd20 pour la reduction de la formation des anticorps contre des médicaments |
| KR102850929B1 (ko) * | 2015-12-09 | 2025-08-27 | 에프. 호프만-라 로슈 아게 | 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체 |
| CA3071618A1 (fr) | 2017-08-08 | 2019-02-14 | F. Hoffmann-La Roche Ag | Traitement a l'obinutuzumab d'un sous-groupe de patients dlbcl |
-
2018
- 2018-08-08 CA CA3071618A patent/CA3071618A1/fr active Pending
- 2018-08-08 CN CN201880051243.4A patent/CN111032692A/zh active Pending
- 2018-08-08 MA MA049830A patent/MA49830A/fr unknown
- 2018-08-08 ES ES18755421T patent/ES2933256T3/es active Active
- 2018-08-08 JP JP2020505912A patent/JP7418322B2/ja active Active
- 2018-08-08 IL IL272418A patent/IL272418B2/en unknown
- 2018-08-08 KR KR1020207006102A patent/KR102799421B1/ko active Active
- 2018-08-08 PE PE2020000199A patent/PE20200738A1/es unknown
- 2018-08-08 TW TW107127631A patent/TWI772488B/zh active
- 2018-08-08 SG SG11202000985XA patent/SG11202000985XA/en unknown
- 2018-08-08 CR CR20200061A patent/CR20200061A/es unknown
- 2018-08-08 UA UAA202001356A patent/UA126204C2/uk unknown
- 2018-08-08 WO PCT/EP2018/071462 patent/WO2019030260A1/fr not_active Ceased
- 2018-08-08 AU AU2018314765A patent/AU2018314765C1/en active Active
- 2018-08-08 MX MX2020001493A patent/MX2020001493A/es unknown
- 2018-08-08 PL PL18755421.7T patent/PL3665196T3/pl unknown
- 2018-08-08 EP EP18755421.7A patent/EP3665196B1/fr active Active
- 2018-08-08 MY MYPI2020000328A patent/MY202382A/en unknown
- 2018-08-08 CN CN202411647297.0A patent/CN119798437A/zh active Pending
-
2020
- 2020-01-31 ZA ZA2020/00680A patent/ZA202000680B/en unknown
- 2020-02-06 US US16/784,021 patent/US11597772B2/en active Active
-
2023
- 2023-02-02 US US18/163,810 patent/US20230348611A1/en active Pending
- 2023-08-24 JP JP2023136335A patent/JP2023179425A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL272418A (en) | 2020-03-31 |
| AU2018314765B2 (en) | 2025-03-20 |
| JP7418322B2 (ja) | 2024-01-19 |
| PL3665196T3 (pl) | 2023-01-23 |
| CN111032692A (zh) | 2020-04-17 |
| TW201910353A (zh) | 2019-03-16 |
| PE20200738A1 (es) | 2020-07-23 |
| CN119798437A (zh) | 2025-04-11 |
| US20230348611A1 (en) | 2023-11-02 |
| NZ761111A (en) | 2024-05-31 |
| MX2020001493A (es) | 2020-03-24 |
| KR102799421B1 (ko) | 2025-04-30 |
| TW202323297A (zh) | 2023-06-16 |
| US11597772B2 (en) | 2023-03-07 |
| IL272418B2 (en) | 2024-09-01 |
| ZA202000680B (en) | 2024-09-25 |
| US20200317800A1 (en) | 2020-10-08 |
| UA126204C2 (uk) | 2022-08-31 |
| WO2019030260A1 (fr) | 2019-02-14 |
| ES2933256T3 (es) | 2023-02-03 |
| AU2018314765C1 (en) | 2025-11-20 |
| JP2023179425A (ja) | 2023-12-19 |
| EP3665196A1 (fr) | 2020-06-17 |
| CA3071618A1 (fr) | 2019-02-14 |
| MY202382A (en) | 2024-04-24 |
| TWI772488B (zh) | 2022-08-01 |
| EP3665196B1 (fr) | 2022-10-19 |
| CR20200061A (es) | 2020-05-23 |
| KR20200035441A (ko) | 2020-04-03 |
| SG11202000985XA (en) | 2020-02-27 |
| AU2018314765A1 (en) | 2020-01-30 |
| IL272418B1 (en) | 2024-05-01 |
| JP2020530002A (ja) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3600130C0 (fr) | Génération de représentation virtuelle d'un traitement orthodontique d'un patient | |
| MA49830A (fr) | Traitement à l'obinutuzumab d'un sous-groupe de patients dlbcl | |
| EP3813634A4 (fr) | Articulation d'instruments médicaux | |
| EP3814567A4 (fr) | Appareil d'entretien de vêtements | |
| EP3515505A4 (fr) | Traitement vaa de la maladie de huntington | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| EP3691549A4 (fr) | Manchon d'occlusion ou de restriction de sang | |
| EP3817747A4 (fr) | Administration ciblée d'agents thérapeutiques à des adipocytes humains | |
| ITUA20163045A1 (it) | Dispositivo spaziatore per il trattamento di un'articolazione del corpo umano | |
| MA53553A (fr) | Traitement post-chirurgical de la douleur | |
| EP4072456A4 (fr) | Cartographie et traitement tissulaire | |
| PT3773558T (pt) | Tratamento combinado de doença artrítica | |
| EP3773632A4 (fr) | Méthodes de traitement de glioblastomes exprimant l'egfrviii | |
| JP1671730S (ja) | 医療用加湿器用タブ用部品 | |
| EP3824131A4 (fr) | Appareil d'entretien de vêtements | |
| MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc | |
| EP4021858A4 (fr) | Traitement d'azoles | |
| PL3634428T3 (pl) | Lek do zapobiegania lub leczenia infekcji rinowirusowej | |
| MA42985A (fr) | Traitement de troubles liés à l'acide biliaire | |
| LT3749308T (lt) | Klasikine fabri liga sergančių pacientų gydymas migalastatu | |
| EP3546449A4 (fr) | Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn | |
| EP3735934A4 (fr) | Instrument d'observation médicale | |
| EP3850534A4 (fr) | Reconstruction de sous-images d'empreinte digitale | |
| EP3898960A4 (fr) | Variants d'alpha-galactosidase humaine | |
| MA53636A (fr) | Agent de traitement de troubles dermatologiques |